Find information on Multiple Sclerosis diagnosis, including ICD-10 codes G35, clinical documentation requirements, diagnostic criteria, MS symptoms, and disease management. Learn about healthcare provider resources for MS, differential diagnosis considerations, and medical coding guidelines for accurate billing and reimbursement. This resource provides valuable information for neurologists, clinicians, medical coders, and other healthcare professionals involved in MS patient care.
Also known as
Multiple sclerosis
Covers all types of multiple sclerosis.
Diseases of the nervous system
Encompasses various neurological disorders, including MS.
Abnormal involuntary movements
Includes tremors and other movement issues seen in MS.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the diagnosis Multiple Sclerosis?
Yes
Is MS relapsing-remitting?
No
Do not code for Multiple Sclerosis. Review clinical documentation for alternative diagnosis.
When to use each related code
| Description |
|---|
| Multiple sclerosis (MS) |
| Clinically isolated syndrome (CIS) |
| Neuromyelitis optica spectrum disorder (NMOSD) |
Inaccurate coding of relapsing-remitting, primary progressive, or secondary progressive MS (G35) impacts reimbursement and quality metrics.
Lack of documentation specifying Expanded Disability Status Scale (EDSS) score leads to undercoding MS severity and lost revenue.
Failure to capture and code related complications like optic neuritis, fatigue, or spasticity (e.g., H52.0, R53.83) impacts data accuracy.
Q: What are the most specific and sensitive diagnostic criteria for multiple sclerosis in patients presenting with atypical symptoms?
A: Diagnosing multiple sclerosis (MS) in patients with atypical symptoms can be challenging. The 2017 McDonald Criteria remain the most widely accepted and sensitive diagnostic criteria, emphasizing dissemination in space and time of MS lesions. For atypical presentations, demonstrating dissemination in space might require advanced imaging techniques like brain and spinal cord MRI with specific protocols for lesion detection, including T2-weighted, FLAIR, and gadolinium-enhanced sequences. Dissemination in time can be established either clinically with two distinct MS attacks or radiologically with new T2 and/or gadolinium-enhancing lesions on follow-up MRI compared to a baseline scan. Furthermore, atypical cases often benefit from comprehensive differential diagnosis including neuromyelitis optica spectrum disorders, other autoimmune conditions, and infectious or metabolic mimickers. Consider implementing a multidisciplinary approach involving neurologists, radiologists, and other specialists to ensure accurate diagnosis and management of atypical MS. Explore how incorporating evoked potentials (VEPs, SSEPs) can further aid in demonstrating dissemination in space, especially in cases with limited MRI findings. Learn more about the utility of cerebrospinal fluid analysis for oligoclonal bands and other MS-related biomarkers in supporting the diagnosis, particularly in challenging cases.
Q: How can I differentiate between radiologically isolated syndrome (RIS) and early-stage multiple sclerosis in clinical practice?
A: Differentiating between radiologically isolated syndrome (RIS) and early-stage multiple sclerosis (MS) depends on the presence or absence of clinical symptoms consistent with MS. RIS, by definition, lacks clinical manifestations of MS despite having MRI findings suggestive of demyelination. These findings typically include T2 hyperintense lesions characteristic of MS in the brain, spinal cord, or optic nerves. In contrast, early-stage MS presents with clinical symptoms like optic neuritis, sensory disturbances, or motor weakness, alongside supporting MRI findings. Longitudinal follow-up is crucial in RIS, as a subset of patients will eventually develop clinically definite MS. Monitoring for new or enlarging lesions on MRI and the emergence of clinical symptoms is essential. Consider implementing a regular surveillance protocol including neurological examinations and periodic MRI scans. Explore how lifestyle modifications, such as smoking cessation and vitamin D supplementation, may impact disease progression in RIS. Learn more about the current research on predictive biomarkers for conversion from RIS to clinically definite MS.
Patient presents with symptoms suggestive of multiple sclerosis (MS). Clinical presentation includes [specific symptoms e.g., optic neuritis, paresthesias, Lhermitte's sign, gait ataxia, fatigue, bladder dysfunction, cognitive impairment]. Neurological examination reveals [specific findings e.g., hyperreflexia, decreased vibratory sensation, internuclear ophthalmoplegia, positive Babinski sign]. Disease modifying therapy (DMT) discussion initiated. Differential diagnosis includes neuromyelitis optica spectrum disorder (NMOSD), transverse myelitis, and other demyelinating diseases. Brain and spinal cord MRI with and without contrast ordered to evaluate for demyelinating lesions disseminated in space and time, fulfilling McDonald criteria for MS diagnosis. Initial laboratory workup including complete blood count (CBC), comprehensive metabolic panel (CMP), vitamin B12 levels, and thyroid stimulating hormone (TSH) ordered to rule out other potential etiologies. Patient education provided regarding MS symptoms, prognosis, and treatment options. Referral to neurology scheduled for further evaluation and management. ICD-10 code G35 assigned. Medical billing codes for evaluation and management (E/M) services, MRI brain and spine, and laboratory tests documented. Follow-up appointment scheduled to review MRI results and discuss treatment plan. Patient advised to return to clinic sooner for any worsening or new neurological symptoms. Patient diagnosed with relapsing-remitting multiple sclerosis (RRMS) based on clinical presentation, MRI findings demonstrating dissemination in space and time, and exclusion of alternative diagnoses. Current exacerbation characterized by [specific symptoms e.g., sensory disturbances, motor weakness, visual changes]. Patient reports prior episodes of [previous MS symptoms]. Treatment with high-dose intravenous corticosteroids initiated to manage acute exacerbation. Discussion regarding long-term disease-modifying therapies (DMTs) for RRMS, including interferon beta, glatiramer acetate, teriflunomide, dimethyl fumarate, and other options, was conducted, considering patient preferences, potential side effects, and cost. Patient expressed understanding of treatment risks and benefits. Referral to physical therapy and occupational therapy initiated to address functional limitations and improve quality of life. Neuropsychological evaluation considered to assess cognitive function. ICD-10 code G35.0 assigned. Medical billing codes for intravenous corticosteroid administration, E/M services, and therapy referrals documented. Patient instructed to follow up with neurology for ongoing disease management and monitoring of treatment response. Patient education materials provided regarding MS relapse management and lifestyle modifications.